Myelodysplastic syndromes Trials in Limoges, France
Conditions / Myelodysplastic syndromes / Limoges, France
Myelodysplastic syndromes is a medical condition with active clinical research programs worldwide.
25 total trials for this combination
Showing top 10 of 25 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT02912208 | Eltrombopag for the Treatment of Thrombocytopenia Due to Low- and Intermediate Risk Myelodysplastic Syndromes | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT01288378 | Empirical Versus Preemptive Antifungal Therapy | COMPLETED | PHASE3 |
| NCT03682536 | A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT02907359 | Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs | COMPLETED | PHASE3 |
| NCT03503409 | IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT01241500 | Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts | COMPLETED | PHASE3 |
| NCT04797780 | Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome | TERMINATED | PHASE3 |
| NCT02598661 | Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) | ACTIVE_NOT_RECRUITING | PHASE2/PHASE3 |
| NCT04935684 | Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation | RECRUITING | PHASE2 |
| NCT04827719 | BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS | COMPLETED | PHASE2 |